160 related articles for article (PubMed ID: 37272173)
41. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
42. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for progressive systemic sclerosis: a retrospective study of outcome and prognostic factors.
Pyka V; Vangala DB; Mika T; Kreuter A; Susok L; Baraliakos X; Treiber H; Schroers R; Nilius-Eliliwi V
J Cancer Res Clin Oncol; 2024 Jun; 150(6):301. PubMed ID: 38850365
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma.
Pession A; Prete A; Locatelli F; Pierinelli S; Pession AL; Maccario R; Magrini E; De Bernardi B; Paolucci P; Paolucci G
Br J Cancer; 1998 Aug; 78(4):528-33. PubMed ID: 9716039
[TBL] [Abstract][Full Text] [Related]
44. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
[TBL] [Abstract][Full Text] [Related]
45. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results.
Matthay KK; O'Leary MC; Ramsay NK; Villablanca J; Reynolds CP; Atkinson JB; Haase GM; Stram DO; Seeger RC
Eur J Cancer; 1995; 31A(4):572-5. PubMed ID: 7576971
[TBL] [Abstract][Full Text] [Related]
46. High-dose chemotherapy and autologous blood stem cell transplantation in children with metastatic neuroblastoma.
Kai T; Ishii E; Matsuzaki A; Inaba S; Suita S; Ueda K
Acta Paediatr Jpn; 1997 Feb; 39(1):54-60. PubMed ID: 9124054
[TBL] [Abstract][Full Text] [Related]
47. Autologous stem cell transplantation for the treatment of neuroblastoma in Korea.
Ryu KH; Ahn HS; Koo HH; Kook H; Kim MK; Kim HK; Ghim T; Moon HN; Seo JJ; Sung KW; Shin HY; Yoo ES; Lyu CJ; Lee YH; Lee H; Cho B; Cho HS; Choi HS; Hah JO; Hwang TJ
J Korean Med Sci; 2003 Apr; 18(2):242-7. PubMed ID: 12692423
[TBL] [Abstract][Full Text] [Related]
48. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
[TBL] [Abstract][Full Text] [Related]
49. [Treatment outcome and prognosis of autologous hematopoietic stem cell transplantation combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma].
Cui XZ; Wang HQ; Liu XM; Zhang HL; Li W
Zhonghua Xue Ye Xue Za Zhi; 2007 Sep; 28(9):609-11. PubMed ID: 18246818
[TBL] [Abstract][Full Text] [Related]
50. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2010 May; (5):CD006301. PubMed ID: 20464740
[TBL] [Abstract][Full Text] [Related]
51. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
[TBL] [Abstract][Full Text] [Related]
52. Analysis of treatment cost for neuroblastoma to the family: a single-center cross-sectional study in China.
Jiang C; Cai S; Duan C; Xu N; Zhou Y; Peng X; Ma X
J Med Econ; 2020 Sep; 23(9):961-966. PubMed ID: 32568600
[TBL] [Abstract][Full Text] [Related]
53. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.
Cai J; Pan C; Tang Y; Chen J; Zhou M; Li B; Xue H; Shen S; Gao Y; Zhang A; Tang J
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1327-1335. PubMed ID: 28283783
[TBL] [Abstract][Full Text] [Related]
54. [Clinical efficacy of combined therapy in children with stage 4 neuroblastoma].
Liang WL; Ye XF; Zhong G; Chen JJ; Dai KL; Cheuk KLD; Mo S; Wang BS; Li CY; Jiang XZ; Xu ZY; Zhou L; Chan I; Chen JL; Chu P; Lee PWP; Chan CFG
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jul; 24(7):759-764. PubMed ID: 35894190
[TBL] [Abstract][Full Text] [Related]
55. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.
Schumacher-Kuckelkorn R; Volland R; Gradehandt A; Hero B; Simon T; Berthold F
Pediatr Blood Cancer; 2017 Jan; 64(1):46-56. PubMed ID: 27654028
[TBL] [Abstract][Full Text] [Related]
56. [Megachemotherapy and autologous hematopoietic stem cell transplantation in children with solid tumours excluding neuroblastoma--experience of Polish paediatric centres].
Drabko K; Choma M; Zaucha-Prazmo A; Wójcik B; Gorczyńska E; Kałwak K; Turkiewicz D; Słociak M; Ussowicz M; Dyla A; Chybicka A; Styczyński J; Debski R; Wysocki M; Goździk J; Ratajczak M; Kowalczyk JR
Med Wieku Rozwoj; 2006; 10(3 Pt 1):785-92. PubMed ID: 17317909
[TBL] [Abstract][Full Text] [Related]
57. Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Tushabe DA; Berthold F
Cochrane Database Syst Rev; 2015 Jan; 1():CD010685. PubMed ID: 25634649
[TBL] [Abstract][Full Text] [Related]
58. [High-dose chemoradiotherapy with bone marrow transplantation as a consolidation treatment of neuroblastoma. Results in 49 unselected patients with stage IV cancer and older than 1 year. Report of the LMCE neuroblastoma group].
Kremens B; Philip T; Bernard JL; Zucker JM
Klin Padiatr; 1987; 199(3):218-23. PubMed ID: 3306132
[TBL] [Abstract][Full Text] [Related]
59. [Dose-enhanced immunochemotherapy followed by first-line autologous peripheral blood stem cell transplantation for young patients with high-risk aggressive B-cell lymphoma: an efficacy and prognostic factor analysis].
Wang Y; Liu W; Huang WY; Lyu R; Li J; Deng SH; Sui WW; Liu H; Wang TY; Yi SH; Liu HM; Qiu LG; Zou DH
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):215-220. PubMed ID: 35405779
[No Abstract] [Full Text] [Related]
60. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
